XTANT MEDICAL Valuation
| XMS Stock | EUR 0.34 0.01 3.03% |
XTANT MEDICAL seems to be fairly valued based on Macroaxis valuation methodology. Our model calculates the value of XTANT MEDICAL HLDGS from analyzing the company fundamentals such as Return On Asset of -0.0619, profit margin of (0.15) %, and Gross Profit of 32.49 M as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that XTANT MEDICAL's price fluctuation is out of control at this time. Calculation of the real value of XTANT MEDICAL HLDGS is based on 3 months time horizon. Increasing XTANT MEDICAL's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the XTANT stock is determined by what a typical buyer is willing to pay for full or partial control of XTANT MEDICAL HLDGS. Since XTANT MEDICAL is currently traded on the exchange, buyers and sellers on that exchange determine the market value of XTANT Stock. However, XTANT MEDICAL's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.34 | Real 0.33 | Hype 0.34 | Naive 0.35 |
The real value of XTANT Stock, also known as its intrinsic value, is the underlying worth of XTANT MEDICAL HLDGS Company, which is reflected in its stock price. It is based on XTANT MEDICAL's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of XTANT MEDICAL's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of XTANT MEDICAL HLDGS helps investors to forecast how XTANT stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of XTANT MEDICAL more accurately as focusing exclusively on XTANT MEDICAL's fundamentals will not take into account other important factors: XTANT MEDICAL Total Value Analysis
XTANT MEDICAL HLDGS is at this time estimated to have takeover price of 0 with market capitalization of 72.54 M, debt of 17.43 M, and cash on hands of 20.31 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the XTANT MEDICAL fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
0 | 72.54 M | 17.43 M | 20.31 M |
XTANT MEDICAL Investor Information
About 75.0% of the company outstanding shares are owned by institutional investors. The company recorded a loss per share of 0.08. XTANT MEDICAL HLDGS had not issued any dividends in recent years. XTANT MEDICAL HLDGS is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.XTANT MEDICAL Asset Utilization
One of the ways to look at asset utilization of XTANT is to check how much profit was generated for every dollar of assets it reports. XTANT MEDICAL HLDGS owns a negative utilization of current and long term assets of -0.0619 %, losing €6.19E-4 for each euro of current and long term assets held by the company. Ineffective asset utilization attests that the company is being less competent with each euro of current and long term assets it owns. Strictly speaking, asset utilization of XTANT MEDICAL HLDGS shows how unsuccessful it operates for each euro spent on its current and long term assets.XTANT MEDICAL Ownership Allocation
XTANT MEDICAL HLDGS secures a total of 108.66 Million outstanding shares. The majority of XTANT MEDICAL HLDGS outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to purchase positions in XTANT MEDICAL HLDGS to benefit from reduced commissions. Therefore, outside corporations are subject to a different set of regulations than regular investors in XTANT MEDICAL HLDGS. Please pay attention to any change in the institutional holdings of XTANT MEDICAL as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company retains, if the real value of the company is less than the current market value, you may not be able to make money on it.XTANT MEDICAL Profitability Analysis
The company reported the revenue of 56.67 M. Net Loss for the year was (2.83 M) with profit before overhead, payroll, taxes, and interest of 32.49 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates XTANT MEDICAL's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in XTANT MEDICAL and how it compares across the competition.
About XTANT MEDICAL Valuation
The stock valuation mechanism determines XTANT MEDICAL's current worth on a weekly basis. Our valuation model uses a comparative analysis of XTANT MEDICAL. We calculate exposure to XTANT MEDICAL's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of XTANT MEDICAL's related companies.Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana. XTANT MEDICAL operates under Medical Devices classification in Germany and is traded on Frankfurt Stock Exchange. It employs 110 people.
8 Steps to conduct XTANT MEDICAL's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates XTANT MEDICAL's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct XTANT MEDICAL's valuation analysis, follow these 8 steps:- Gather financial information: Obtain XTANT MEDICAL's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine XTANT MEDICAL's revenue streams: Identify XTANT MEDICAL's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research XTANT MEDICAL's industry and market trends, including the size of the market, growth rate, and competition.
- Establish XTANT MEDICAL's growth potential: Evaluate XTANT MEDICAL's management, business model, and growth potential.
- Determine XTANT MEDICAL's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate XTANT MEDICAL's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for XTANT Stock analysis
When running XTANT MEDICAL's price analysis, check to measure XTANT MEDICAL's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XTANT MEDICAL is operating at the current time. Most of XTANT MEDICAL's value examination focuses on studying past and present price action to predict the probability of XTANT MEDICAL's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XTANT MEDICAL's price. Additionally, you may evaluate how the addition of XTANT MEDICAL to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |